These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 24106956)

  • 1. Pancreatic atrophy--a new late toxic effect of sorafenib.
    Hescot S; Vignaux O; Goldwasser F
    N Engl J Med; 2013 Oct; 369(15):1475-6. PubMed ID: 24106956
    [No Abstract]   [Full Text] [Related]  

  • 2. Pancreatic atrophy from sorafenib.
    Sullivan S
    N Engl J Med; 2014 Jan; 370(2):186. PubMed ID: 24401074
    [No Abstract]   [Full Text] [Related]  

  • 3. Pancreatic atrophy from sorafenib.
    Hescot S; Vignaux O; Goldwasser F
    N Engl J Med; 2014 Jan; 370(2):186. PubMed ID: 24401073
    [No Abstract]   [Full Text] [Related]  

  • 4. Case of sorafenib-induced thyroid storm.
    Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
    J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib: osteonecrosis of the jaw.
    Prescrire Int; 2015 Nov; 24(165):269. PubMed ID: 26688904
    [No Abstract]   [Full Text] [Related]  

  • 6. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
    Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
    Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
    [No Abstract]   [Full Text] [Related]  

  • 7. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
    Prescrire Int; 2016 Feb; 25(168):37. PubMed ID: 27042725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
    El Tal AK; Remichofsky CJ; Mehregan DA; Ganger LK
    Int J Dermatol; 2013 Dec; 52(12):1538-41. PubMed ID: 23676092
    [No Abstract]   [Full Text] [Related]  

  • 10. Pustular eruption induced by sorafenib in a case of psoriasis vulgaris.
    Maki N; Komine M; Takatsuka Y; Maekawa T; Murata S; Ohtsuki M
    J Dermatol; 2013 Apr; 40(4):299-300. PubMed ID: 23398293
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis.
    Phillip V; Zahel T; Bärtl K; Rasch S; Ebert O; Schmid RM; Rummeny E; Algül H
    Pancreatology; 2016; 16(4):621-4. PubMed ID: 26968257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
    García-Martín A; López-Ibarra Lozano PJ; Triviño-Ibáñez EM; Escobar-Jiménez F
    Endocrinol Nutr; 2013 Mar; 60(3):152-3. PubMed ID: 22565118
    [No Abstract]   [Full Text] [Related]  

  • 13. Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
    Kusari A; Borok J; Han AM; Valderrama AJ; Friedlander SF
    Pediatr Dermatol; 2018 Jul; 35(4):e206-e209. PubMed ID: 29766555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure associated with small molecule tyrosine kinase inhibitors.
    Imran TF; Shah R; Ha AS; Thomas R; Joseph J
    Int J Cardiol; 2016 Mar; 206():110-1. PubMed ID: 26785036
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H; Han SH; Kang H; Park K
    Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
    Herzog TJ; Scambia G; Kim BG; Lhommé C; Markowska J; Ray-Coquard I; Sehouli J; Colombo N; Shan M; Petrenciuc O; Oza A
    Gynecol Oncol; 2013 Jul; 130(1):25-30. PubMed ID: 23591401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
    Le Jeune S; Des Guetz G; Bihan H; Cohen R; Coindre JM; Mourad JJ
    J Clin Oncol; 2013 Mar; 31(9):e118-21. PubMed ID: 23341512
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
    Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
    Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
    Hung CT; Chiang CP; Wu BY
    J Dermatol; 2012 Dec; 39(12):1076-7. PubMed ID: 22724918
    [No Abstract]   [Full Text] [Related]  

  • 20. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
    Kashima T; Ohno Y; Tachibana M
    Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.